In NIH3T3 fibroblasts, galunisertib monohydrate inhibited TGFβ1-stimulated proliferation with an IC50 of 0.40 μM (SE 0.06 μM). IC50 values exceeded 20 μM for PDGF- or bFGF-stimulated proliferation in the same assay. [1]
In a gastric-cancer scratch assay, 50 μM LY2157299 reduced wound closure by Hs746T cells over 72 h. This high-concentration migration result does not by itself establish target specificity. [2]
Growth responses depended on the tumor model. In an initial 66-model xenograft-derived clonogenic panel tested up to 10 μM, galunisertib monohydrate inhibited one model, stimulated 15 and produced no response in 50 under the authors’ criteria. A selected higher-concentration retest also contained inhibited, unchanged and stimulated samples. [3]
Kinase competition-binding profile
Biochemical assay · Panel of 456 wild-type and disease-relevant mutant kinases [1]
The ATP-free binding panel supports interaction with TGFβRI/ALK5, with stronger reported binding potency for ALK4 and additional submicromolar interactions. These non-standard three-point IC50 values are not cellular potency or enzyme catalytic IC50 values.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.2, 2 and 20 μM
- Method
- KINOMEscan competition binding against immobilized ligand, measured as kinase capture versus control
- Vehicle
- 4% final DMSO
- Reported limits
- Binding incubation duration not specified in the reported panel method.
Methods and source locations
Compound reported in the paper: Galunisertib (LY2157299); Compound label in the paper: LY2157299 monohydrate
Evidence describes the reported material; no mass conversion or validation of the current Adooq lot is implied.
Table 1; Figure 1C; Results s2_1; Methods s4_1 (KINOMEscan)
TGFβRI (ALK5) competition binding: ATP-free KINOMEscan competition binding; three-point concentration response. — Table 1; Results s2_1; Methods s4_1 (KINOMEscan)
ALK4/ACVR1B competition binding: Same competition-binding panel, not a cellular treatment dose. — Table 1; Methods s4_1 (KINOMEscan)
TGFβR2 competition binding: Same ATP-free competition-binding panel. — Table 1; Methods s4_1 (KINOMEscan)
Growth-factor controls in fibroblast proliferation
Cell-based study · NIH3T3 mouse fibroblasts [1]
Galunisertib inhibited TGFβ1-driven proliferation while PDGF- and bFGF-driven proliferation had reported IC50 values above 20 μM. This supports pathway dependence in this assay, rather than general growth inhibition.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response titration; exact full series not tabulated
- Exposure duration
- 2 h compound pretreatment; 12–18 h after growth-factor addition, followed by 6 h thymidine labeling
- Method
- 3H-thymidine incorporation; medium-alone and growth-factor comparison groups
- Vehicle
- DMSO-containing dilution medium; final well DMSO percentage not specified
- Reported limits
- Growth-factor concentrations and full galunisertib series not specified in this method.
Methods and source locations
Compound reported in the paper: Galunisertib (LY2157299); Compound label in the paper: LY2157299 monohydrate
Evidence describes the reported material; no mass conversion or validation of the current Adooq lot is implied.
Table 3; Figure 2B; Results s2_2; Methods s4_5
TGFβ1-stimulated NIH3T3 proliferation: 3H-thymidine incorporation; Table 3 specifies SE and a minimum of three assay runs. Figure 2 caption states four runs, each with 3–8 replicates. — Table 3; Figure 2B and caption; Methods s4_5
PDGF-stimulated NIH3T3 proliferation: Growth-factor specificity control in the same proliferation assay. — Table 3; Methods s4_5
bFGF-stimulated NIH3T3 proliferation: Growth-factor specificity control in the same proliferation assay. — Table 3; Methods s4_5
Variable clonogenic response in tumor xenograft-derived cells
Cell-based study · Initial panel of 66 tumor xenograft-derived samples; selected 24-model higher-concentration retest [3]
Most samples were not inhibited, and some showed growth stimulation. The first panel and selected higher-concentration retest belong to one clonogenic screening design; they are not pooled as independent samples. The separate melanoma viability panel is not included in these counts.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.03–10.0 μM initially; 1.0–80.0 μM for selected retests
- Exposure duration
- Continuous exposure for 7–20 days, evaluated at maximum colony formation
- Method
- Soft-agar colony formation; image-based colony counts
- Vehicle
- 0.3% DMSO solvent control
- Reported limits
- Per-model replicate counts not specified in the selected main-text method.
Methods and source locations
Compound reported in the paper: Galunisertib (LY2157299); Compound label in the paper: LY2157299 monohydrate
Evidence describes the reported material; no mass conversion or validation of the current Adooq lot is implied.
Results Sec13, first series; Figure 1a; Methods Sec3–Sec4
Response categories in initial 66-model clonogenic panel: Image-based colony counting versus 0.3% DMSO solvent control. Inhibition T/C ≤75%; no response 75% < T/C <125%; stimulation T/C ≥125%. — Results Sec13, first experimental series; Figure 1a; Methods Sec4
Response categories in selected 24-model higher-concentration retest: Selected retest; not an independent or unbiased response-rate estimate. Same colony-response criteria. — Results Sec13, first experimental series; Figure 1a; Methods Sec3–Sec4
Reduced wound closure in a gastric-cancer migration assay
Cell-based study · Hs746T gastric cancer cells, with NCI-N87 comparator cells [2]
At 50 μM, LY2157299 reduced scratch wound closure in Hs746T cells relative to the LY− group. NCI-N87 cells had little wound closure in either plotted condition. This is a migration-associated endpoint at a high test concentration; it does not alone establish target-specific inhibition or cytotoxicity independence.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 μM
- Exposure duration
- Wound width measured after 72 h
- Method
- Scratch wound-healing assay; immediate wound width used for normalization
- Reported limits
- Vehicle and treatment-specific final solvent percentage not reported in the migration method; n=20 is caption terminology, without an explicit biological-versus-technical replicate definition.
Methods and source locations
Compound reported in the paper: Galunisertib (LY2157299); Compound label in the paper: LY2157299 (LY)
Evidence describes the reported material; no mass conversion or validation of the current Adooq lot is implied.
Methods Sec10–Sec11; Results Sec23; Figure 8e and caption
Scratch wound closure in Hs746T cells with LY2157299: Scratch assay; wound width after 72 h normalized to immediate post-scratch width. Figure 8e includes LY− and LY+ comparisons in Hs746T and NCI-N87 cells. No exact bar heights inferred. — Methods Sec11; Results Sec23; Figure 8e and caption